Abbott Laboratories 2014 Annual Report Download - page 31

Download and view the complete annual report

Please find page 31 of the 2014 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

29
ABBOTT 2014 ANNUAL REPORT
Alberto Wilson of Bogota, Colombia, is a busy
commercial advisor with active twin 11-year-
old sons, Andres and Phillip. Whenever he
can, Alberto loves to spend time with his
boys, taking walks in the neighborhood
park, watching them play soccer, and visiting
historic places and the scenic mountains that
flank the city.
Alberto loves to lead an active lifestyle. So
when he learned that he was suering from
high cholesterol, he knew he had to find a
way to manage his condition. He relied on
our Normolip brand fenofibrate to help lower
his triglycerides and raise his levels of high-
density lipoprotein, also known as HDL, the
“good” cholesterol. Normolip is just one drug
in a portfolio that includes some of the world’s
most-trusted brands.
In 2014, Abbott made a series of strategic
moves that will refocus and strengthen
this business. First, we completed our
acquisitions of two regional branded-generic
pharmaceutical companies to expand our
footprint in important markets. In September,
we added CFR Pharmaceuticals, one of the
leading branded-generics companies in Latin
America, based in Santiago, Chile. With
this deal, Abbott became one of the top ten
pharmaceutical companies in Latin America.
At the end of the year, we completed our
acquisition of Veropharm, making us a top-five
branded-generics company in Russia. And in
July, we agreed to sell the Developed Markets
portion of this business to Mylan Inc. This
transaction, which was completed in February
2015, will allow us to focus our energies
entirely on driving balanced, sustainable, and
faster growth in developing markets.
Bogota,
Colombia